Monte Rosa Therapeutics Management
Management criteria checks 2/4
Monte Rosa Therapeutics' CEO is Markus Warmuth, appointed in Jan 2020, has a tenure of 4.5 years. total yearly compensation is $3.63M, comprised of 17% salary and 83% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth $1.64M. The average tenure of the management team and the board of directors is 1.8 years and 3.8 years respectively.
Key information
Markus Warmuth
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 17.0% |
| CEO tenure | 4.5yrs |
| CEO ownership | 0.7% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20
Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$4m | US$616k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$133m |
| Jun 30 2023 | n/a | n/a | -US$125m |
| Mar 31 2023 | n/a | n/a | -US$117m |
| Dec 31 2022 | US$4m | US$582k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$94m |
| Mar 31 2022 | n/a | n/a | -US$86m |
| Dec 31 2021 | US$5m | US$525k | -US$74m |
| Sep 30 2021 | n/a | n/a | -US$70m |
| Jun 30 2021 | n/a | n/a | -US$57m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$2m | US$465k | -US$36m |
Compensation vs Market: Markus's total compensation ($USD3.63M) is above average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Markus's compensation has been consistent with company performance over the past year.
CEO
Markus Warmuth (53 yo)
4.5yrs
Tenure
US$3,627,130
Compensation
Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.5yrs | US$3.63m | 0.68% $ 1.6m | |
| Chief Medical Officer | 3.1yrs | US$1.49m | 0% $ 0 | |
| Chief Operating Officer | 3.3yrs | no data | no data | |
| Chief Data & Information Officer | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior VP and Head of IR & Strategic Finance | less than a year | no data | no data | |
| Chief Business & Legal Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Drug Discovery | 1.3yrs | no data | no data | |
| Vice President & Corporate Controller | no data | no data | 0.025% $ 61.3k |
1.8yrs
Average Tenure
51yo
Average Age
Experienced Management: GLUE's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.5yrs | US$3.63m | 0.68% $ 1.6m | |
| Independent Director | 3.6yrs | US$150.88k | 0% $ 0 | |
| Independent Chairman of the Board | 3.8yrs | US$153.38k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.88k | 0.016% $ 39.4k | |
| Independent Director | 3.8yrs | no data | no data | |
| Independent Director | less than a year | US$202.10k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$339.56k | 0% $ 0 | |
| Scientific Advisor & Member of Scientific Advisory Board | less than a year | US$1.42m | 0% $ 0 | |
| Independent Director | 4yrs | US$140.88k | 0% $ 0 |
3.8yrs
Average Tenure
55yo
Average Age
Experienced Board: GLUE's board of directors are considered experienced (3.8 years average tenure).